What prophylactic drug is recommended for a patient exposed to tuberculosis?

Prophylactic Drug for PTB Exposure

Isoniazid for 6-9 months is the recommended prophylactic drug for patients exposed to tuberculosis, with 9 months preferred for HIV-infected individuals or those with radiographic evidence of prior TB 1, 2.

Primary Prophylaxis Regimen Options

The standard approach depends on the drug susceptibility of the source case and patient characteristics:

For Drug-Susceptible TB Exposure

First-line options:

• Isoniazid alone for 6 months (acceptable) or 9 months (preferred for higher-risk patients) 1, 2
• Rifampin plus isoniazid for 3 months - alternative shorter regimen 1
• Rifampin alone for 4 months - useful when isoniazid cannot be tolerated 2

The British Thoracic Society guidelines specifically recommend either isoniazid for 6 months or the 3-month rifampin/isoniazid combination for children found at contact screening with positive tuberculin tests but normal chest radiographs 1.

For Drug-Resistant TB Exposure

For rifampin-resistant (MDR-TB) exposure:

• Rifampin and pyrazinamide daily for 2 months 2
• If pyrazinamide intolerance: rifampin daily for 4 months 2

For multidrug-resistant (isoniazid + rifampin resistant) exposure:

• Pyrazinamide plus ethambutol for 6-12 months, OR
• Pyrazinamide plus fluoroquinolone (levofloxacin/ofloxacin) for 6-12 months 2
• Duration: 6 months for immunocompetent contacts, 12 months for immunocompromised 2

For fluoroquinolone-resistant strains (pre-XDR/XDR-TB):

• Recent evidence supports moxifloxacin-based (4 months) or bedaquiline-based (3 months) regimens with excellent safety profiles and 95% completion rates 3

Critical Prerequisites Before Starting Prophylaxis

Active TB disease must be ruled out through:

• Clinical history and physical examination for TB symptoms (fever, cough, weight loss, night sweats)
• Chest radiography
• Bacteriologic studies when indicated 2

This is non-negotiable - giving prophylactic monotherapy to someone with active disease will create drug resistance.

Special Population Considerations

HIV-Infected Patients

• Always use 9 months of isoniazid (not 6 months) 2
• Prophylaxis recommended regardless of tuberculin test results if exposed to infectious TB 4
• Add pyridoxine 10 mg daily to prevent peripheral neuropathy 1

Pregnant Women

• For HIV-negative pregnant women: Isoniazid for 9 or 6 months is recommended 2
• If high risk for progression (HIV-infected or recent infection): start immediately, even in first trimester 2
• If lower risk: some experts recommend waiting until after delivery 2

Children and Adolescents

• Isoniazid for 9 months is the standard regimen 2
• Can be given daily or twice-weekly 2

Patients on Protease Inhibitors

Rifampin induces CYP3A enzymes and dramatically reduces protease inhibitor levels. Three options 1:

1. Discontinue protease inhibitor temporarily (preferred option)
2. Omit rifampin and extend treatment to 18 months
3. Substitute rifabutin for rifampin with dose adjustment

Monitoring and Pyridoxine Supplementation

Add pyridoxine 10 mg daily for patients at increased risk of neuropathy 1:

• Diabetics
• Alcoholics
• HIV-positive patients
• Chronic renal failure
• Malnutrition

Baseline liver function testing indicated for 2:

• HIV infection
• Pregnant women and immediate postpartum period (within 3 months)
• History of chronic liver disease (hepatitis B/C, alcoholic hepatitis, cirrhosis)
• Regular alcohol use
• Pre-existing liver disorder

Monthly clinical monitoring is essential - assess for hepatitis symptoms (fever, malaise, vomiting, jaundice) and medication adherence 2, 4.

Common Pitfalls to Avoid

1. Starting prophylaxis without ruling out active disease - this creates drug resistance
2. Using 6 months of isoniazid in HIV-infected patients - they need 9 months
3. Forgetting pyridoxine in high-risk patients - preventable peripheral neuropathy
4. Continuing rifampin with protease inhibitors - leads to treatment failure of both conditions
5. Not checking drug susceptibility of source case - may give ineffective prophylaxis for resistant strains

Evidence for Effectiveness

Prophylaxis reduces TB disease development significantly. In one cohort study of HIV-infected patients, tuberculosis incidence was 80% lower in those receiving prophylaxis compared to those who declined, even after adjusting for CD4 count, viral load, and antiretroviral therapy 5. More recent data shows TB incidence was 4 times higher among eligible individuals who declined prophylaxis versus those who initiated it 3.